Document is current
Any future updates will be listed below
-
Authors
Treadway, Michael T. https://orcid.org/0000-0002-5913-114X
Etuk, Sarah M.
Cooper, Jessica A.
Hossein, Shabnam
Hahn, Evan
Betters, Samantha A.
Liu, Shiyin https://orcid.org/0009-0001-6519-6230
Arulpragasam, Amanda R.
DeVries, Brittany A. M.
Irfan, Nadia
Nuutinen, Makiah R.
Wommack, Evanthia C.
Woolwine, Bobbi J.
Bekhbat, Mandakh
Kragel, Philip A. https://orcid.org/0000-0001-9463-6381
Felger, Jennifer C. https://orcid.org/0000-0003-4354-2267
Haroon, Ebrahim https://orcid.org/0000-0002-8817-1116
Miller, Andrew H. https://orcid.org/0000-0001-8260-7997
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH108605, K01MH126308, R01MH112076, R01MH112076)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 14 February 2024
Revised: 22 August 2024
Accepted: 5 September 2024
First Online: 17 September 2024
Competing interests
: In the past 3 years, MTT has been a paid consultant to Boehringer Ingelheim. AHM has been a paid consultant to Cerevel Therapeutics, Sirtsei Pharmaceuticals LLC and Freedom Biosciences. None of these entities contributed to the current work, and all opinions herein are solely those of the authors. All other authors report no conflicts of interest, financial or otherwise.
: All study procedures were performed in accordance with approved guidelines and relevant regulations. The Emory Institutional Review Board reviewed and approved all procedures described in this study (IRB00087941), and all participants provided written informed consent.
